Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Worldwide Offices
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global 2017 Stem Cells Strategic Business Report - Offering Potential for Breakthrough Therapeutic Discoveries - Research and Markets

This image opens in the lightbox

News provided by

Research and Markets

21 Jun, 2017, 15:15 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, June 21, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Stem Cells - Global Strategic Business Report" report to their offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024.

This report analyzes the worldwide markets for Stem Cell Technologies in US$ Million. Market data and analytics are derived from primary and secondary research.

The report profiles 66 companies including many key and niche players such as:

  • Athersys, Inc. (USA)
  • Apceth GmbH & Co.KG (Germany)
  • AVIVA BioSciences Corporation (USA)
  • BioE, Inc. (USA)
  • Bone Therapeutics SA (Belgium)
  • Cesca Therapeutics, Inc. (USA)
  • Cryo-Cell International, Inc. (USA)
  • Cytori Therapeutics, Inc. (USA)
  • ESI BIO, a Division of BioTime Inc. (USA)
  • Gamida Cell Ltd. (Israel)
  • Holostem Terapie Avanzate (Italy)
  • International Stem Cell Corporation (USA)
  • Kangstem Biotech., Ltd. (Korea)
  • Lonza Group Ltd (Switzerland)
  • Mesoblast Ltd. (Australia)
  • Neuralstem, Inc. (USA)
  • Nuvasive, Inc. (USA)
  • Osiris Therapeutics, Inc. (USA)
  • OncoMed Pharmaceuticals, Inc (USA)
  • PROMETHERA Biosciences S.A.N.V (Belgium)
  • Reliance Life Sciences (India)
  • ReNeuron Group Plc. (UK)
  • STEMCELL Technologies, Inc. (Canada)
  • Stemedica Cell Technologies, Inc (USA)
  • Stempeutics Research Pvt. Ltd. (India)
  • Takara Bio USA Inc (USA)
  • TiGenix NV (Belgium)
  • U.S Stem Cell, Inc. (USA)
  • ViaCord, LLC (USA)

Key Topics Covered:

1. INDUSTRY OVERVIEW
Stem Cells
Offering Potential for Breakthrough Therapeutic Discoveries
Select Approved Stem Cell Products
Stem Cells Bypass Use of Animal Models in Drug Discovery Programs
Trends Related to Stem Cell Clinical Trials
Select Stem Cell Pipeline Analysis
Current & Future Analysis
Stem Cell Research Funding Policies across the World
Japan and US
Pioneering Induced Pluripotent Stem Cell (iPSC) Research
Adult Stem Cells Deemed More Ethical, More Research Needed to Increase Clinical Applications
Dental Mesenchymal Stem Cells
Emergence of a Niche Market
For-Profit, Unregulated Clinics: The Flipside of Stem Cell Research
Unproven Therapies Do Online Rounds as Effective Treatment Options
A Cause of Concern

2. STEM CELL RESEARCH INNOVATIONS
Researchers at UCLA Successfully Develop 3D Lung Organoids using Stem Cells
Embryonic Stem Cell Gene Nanog Found to Reverse Aging
Canadian and Dutch Scientists Finds the Genetic Switch to Increase Stem Cell Volume from Cord Blood
The Boston Program Pioneers Cell-based Personalized Diabetes Treatment
iPSCs Provide Valuable Source for Retinal Transplants and Other Applications
Albumin-Free Culture of Pluripotent Stem Cells Enables Application in Cardiac Disorders
Stem Cell Therapy
An Alternative to Orthopedic Surgery in Younger Patients?
Application of Plant Stem Cells in Cosmetic Treatments
Myths Busted
Adverse Reactions of Stem Cell-Face Lift Therapy
Stem Cell-Breast Enhancement
Other Innovations Using Stem Cells
New Stem Cell Software & Products

3. PRODUCT OVERVIEW
Stem Cell Research
Stem Cells
Description
Types of Stem Cells
Embryonic Stem Cells
mES and hES
R-NSCs
Adult Stem Cells
Hematopoietic Stem Cells
Mesenchymal Stem Cells
Umbilical Cord Stem Cells
Neuronal Stem Cells
Dental Stem Cells
Pluripotent Adult Stem Cells
Other Key Cell Types
The Stem Cell Line
Cell Division
Stem Cells
Properties
Ability to Renew on its Own
Potency
Definitions of Various Potencies
Identification of Stem Cells
Stem Cells
Applications
History of Stem Cells
Stem Cells
Services and Products
Significance of Stem Cell Products/Services

4. PRODUCT LAUNCHES
Minerva Biotechnologies Launches AlphaSTEM, a Naïve Stem Cell Culture System
Takara Bio Launches Human iPSC-Derived Beta Cells for Drug Screening and Diabetes Research
RenovaCare Develops New Stem Cell Device for Burn Injuries
Mesoblast Launches the World's First Off-The-Shelf Stem Cell Treatment
Mesoblast Licensee launches first stem cell product in Japan
Stempeutics Research Receives Approval for India's First Stem Cell Based Drug

5. CLINICAL TRIALS
Nature Cell Commences Phase I and II Clinical Trials of ASTROSTEM' in the US for Treating Alzheimer
Tisch MS Research Center Commences Phase II Stem Cell Clinical Trial for MS
Canadian Clinical Trial to Test Neural Stem Cells in Patients with Spinal Cord Injuries
Neuralstem's ALS Stem Cell Therapy Exhibits Safety and Efficacy in Early Clinical Trials
The University of Michigan Commences Large Scale Clinical Trials for ALS Therapy
Bionomics Receives FDA Approval for Phase I Clinical Trial in Cancer Patients
AHSCT Shows Reduced Brain Lesions in Phase 2 Clinical Trial
Neuralstem's Neural Stem Cell Treatment Meets Primary Safety Endpoints in Phase 2 Trials

6. RECENT INDUSTRY ACTIVITY
GE Health Acquires Biosafe
Human Longevity Acquires Lifebank
AbbVie to Acquire Stemcentrx and Its Lead Asset Rova-T
Thorn Medical Acquires Okyanos Holding Company
Bio-Techne Corporation Acquires Zephyrus Biosciences
Astellas Pharma to Complete Acquisition of Ocata Therapeutics
Bayer Launches Stem Cell Therapy Company BlueRock Therapeutics
apceth Signs License Option Agreement with Cynata Therapeutics Ltd
StemBioSys Announces European Distribution Agreement with Cellaviva AB of Sweden
Fujifilm Holdings Acquires Cellular Dynamics International
American CryoStem Corporation Acquires Biolife Cell Bank
NeoStem Announces Plans to Change Name to Caladrius Biosciences Reflecting Transformation into Immunotherapy Company
ESI BIO Announces Alliance Agreement with Pivotal Scientific Ltd for Distribution of Stem Cell Products
TiGenix and Lonza Signs Agreement for the Manufacture of Stem Cell-based Treatment
AlloSource Receives Patent for AlloStem® Cellular Bone Allograft

Total Companies Profiled: 66 (including Divisions/Subsidiaries 69)

  • The United States (39)
  • Canada (1)
  • Japan (1)
  • Europe (13)
  • - Germany (2)
  • - The United Kingdom (5)
  • - Italy (1)
  • - Rest of Europe (5)
  • Asia-Pacific (Excluding Japan) (12)
  • Middle East (1)
  • Latin America (1)

For more information about this report visit https://www.researchandmarkets.com/research/vw64g5/stem_cells

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • PR Newswire Amplify™
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.